SGLT2 inhibitors for treating diabetes in people with chronic kidney disease

This is a protocol for a Cochrane Review (intervention). The objectives are as follows:

This review aims to assess the benefits and harms of SGLT2 inhibitors for lowering glucose levels in people with diabetes and CKD.

This is a protocol.

Published:

5 October 2022

Authors:

Natale P, Tunnicliffe DJ, Saglimbene VM, Toyama T, Gargano L, Stallone G, Ruospo M, Gesualdo L, Strippoli GFM

Was this helpful? Donate.

If you found this evidence helpful, please consider donating to Cochrane. We are a charity that produces accessible evidence to help people make health and care decisions.
Donate
Print
PDF
Citation
Natale P, Tunnicliffe DJ, Saglimbene VM, Toyama T, Gargano L, Stallone G, Ruospo M, Gesualdo L, Strippoli GFM. SGLT2 inhibitors for treating diabetes in people with chronic kidney disease (Protocol). Cochrane Database of Systematic Reviews 2022, Issue 10. Art. No.: CD015588. DOI: 10.1002/14651858.CD015588.